Compare Biocon with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ZYDUS LIFESCIENCES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON ZYDUS LIFESCIENCES BIOCON /
ZYDUS LIFESCIENCES
 
P/E (TTM) x 41.4 15.9 261.0% View Chart
P/BV x 5.4 2.9 190.1% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 BIOCON    ZYDUS LIFESCIENCES
EQUITY SHARE DATA
    BIOCON
Mar-21
ZYDUS LIFESCIENCES
Mar-21
BIOCON /
ZYDUS LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs488509 95.7%   
Low Rs275259 106.2%   
Sales per share (Unadj.) Rs59.2147.5 40.1%  
Earnings per share (Unadj.) Rs7.720.9 36.9%  
Cash flow per share (Unadj.) Rs13.728.0 48.9%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Avg Dividend yield %00.9 0.0%  
Book value per share (Unadj.) Rs62.3126.9 49.1%  
Shares outstanding (eoy) m1,200.001,023.74 117.2%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x6.42.6 247.3%   
Avg P/E ratio x49.418.4 268.8%  
P/CF ratio (eoy) x27.913.7 203.0%  
Price / Book Value ratio x6.13.0 202.3%  
Dividend payout %016.8 0.0%   
Avg Mkt Cap Rs m457,350393,092 116.3%   
No. of employees `000NANA-   
Total wages/salary Rs m17,41022,548 77.2%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m71,058151,022 47.1%  
Other income Rs m6,052449 1,347.9%   
Total revenues Rs m77,110151,471 50.9%   
Gross profit Rs m13,14531,335 41.9%  
Depreciation Rs m7,1517,248 98.7%   
Interest Rs m5771,688 34.2%   
Profit before tax Rs m11,46922,848 50.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2151,472 150.5%   
Profit after tax Rs m9,25421,376 43.3%  
Gross profit margin %18.520.7 89.2%  
Effective tax rate %19.36.4 299.8%   
Net profit margin %13.014.2 92.0%  
BALANCE SHEET DATA
Current assets Rs m76,00487,160 87.2%   
Current liabilities Rs m42,10178,613 53.6%   
Net working cap to sales %47.75.7 843.0%  
Current ratio x1.81.1 162.8%  
Inventory Days Days13733 410.3%  
Debtors Days Days6376 82.7%  
Net fixed assets Rs m106,142140,943 75.3%   
Share capital Rs m6,0001,024 585.9%   
"Free" reserves Rs m68,728128,899 53.3%   
Net worth Rs m74,728129,923 57.5%   
Long term debt Rs m29,6166,095 485.9%   
Total assets Rs m182,146228,103 79.9%  
Interest coverage x20.914.5 143.6%   
Debt to equity ratio x0.40 844.8%  
Sales to assets ratio x0.40.7 58.9%   
Return on assets %5.410.1 53.4%  
Return on equity %12.416.5 75.3%  
Return on capital %11.518.0 64.0%  
Exports to sales %00-   
Imports to sales %7.210.5 67.9%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m5,08415,911 32.0%   
Fx inflow Rs m11,79163,535 18.6%   
Fx outflow Rs m5,08415,911 32.0%   
Net fx Rs m6,70747,624 14.1%   
CASH FLOW
From Operations Rs m11,59732,930 35.2%  
From Investments Rs m-36,247-7,225 501.7%  
From Financial Activity Rs m25,640-25,489 -100.6%  
Net Cashflow Rs m723-905 -79.9%  

Share Holding

Indian Promoters % 39.7 74.9 53.1%  
Foreign collaborators % 20.9 0.0 -  
Indian inst/Mut Fund % 24.0 15.4 155.3%  
FIIs % 15.6 2.5 617.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.4 25.1 156.7%  
Shareholders   347,911 408,017 85.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   CIPLA    SUN PHARMA    LUPIN    DR. REDDYS LAB    AUROBINDO PHARMA    



Today's Market

SGX Nifty Trades Flat, Maruti Suzuki Acquires Stake in AI Firm, Zomato Q4 Results, and Top Buzzing Stocks Today(Pre-Open)

On Monday, Indian share markets failed to keep up early gains and ended marginally lower.

Related Views on News

Cadila Healthcare Reports 73% Rise in Profits (Views On News)

May 28, 2021

A look into the company's quarter four financial performance.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


May 23, 2022 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS